Characteristics and outcome of SARS-CoV-2 infection in cancer patients.
Clémence Basse(Université de Versailles Saint-Quentin-en-Yvelines), Paul Cottu(Université Paris Sciences et Lettres), François‐Clément Bidard(Inserm), Nathalie Cassoux(Institut Curie), Audrey Bellesœur(Hôpital Cochin), Vincent Servois(Université Paris Sciences et Lettres), Laurence Bozec(Institut Curie), Sandra Malak(Institut Curie), Aurélien Noret(Institut Curie), Marie-Ange Massiani(Institut Curie), Maxime Frélaut(Institut Curie), Anne-Sophie Bouyer(Institut Curie), Irène Kriegel(Institut Curie), Perrine Vuagnat(Université de Versailles Saint-Quentin-en-Yvelines), Pauline Moreau(Institut Curie), Carole Bouleuc(Institut Curie), D. Vanjak(Institut Curie), Alexis Burnod(Institut Curie), Xavier Paolettí(Inserm), G. Dhonneur(Institut Curie), G. Bilger(Institut Curie), Sarah Diakite(Institut Curie), Toulsie Ramtohul(Université Paris Sciences et Lettres)
Cited by 18
Related Papers
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
|Journal of Clinical Oncology|2022|676
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
Recommendations for Bowel Obstruction With Peritoneal Carcinomatosis
|Journal of Pain and Symptom Management|2014|139
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
|Breast Cancer Research|2020|125